UAE Depression Therapeutics Market Report 2022 to 2030

UAE Depression Therapeutics Market Analysis

$ 3999

UAE depression therapeutics market is expected to grow from $51 Mn in 2022 to $82 Mn in 2030 with a CAGR of 6.2% for the forecasted year 2022-30. The growing awareness of depression and the supportive government initiatives to minimize the stigma associated with mental health disorders in the UAE are the major market drivers. The UAE depression therapeutics market is segmented by drug type, therapies, indication, and end users. Sahara Pharmaceutical, Viatris, and Allergan are the major players in the UAE depression therapeutics market.

ID: IN10AEPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Parul Choudhary

Buy Now

UAE Depression Therapeutics Market Executive Analysis

UAE depression therapeutics market is expected to grow from $51 Mn in 2022 to $82 Mn in 2030 with a CAGR of 6.2% for the forecasted year 2022-30. The future holds growth for the UAE's healthcare industry. According to the Dubai Chamber of Commerce and Industry, revenue generated within the overall UAE healthcare sector is anticipated to increase by 7.5% annually to hit $10.7 Bn by 2025. Meanwhile, it is anticipated that healthcare expenditure will increase to 4.6% of GDP by 2026 and 5.1% of GDP by 2029. With increased government initiatives, the UAE healthcare industry is expanding at an astounding rate. Additionally, the UAE government is significantly enhancing and extending its healthcare system to create a powerful, top-notch healthcare infrastructure. To improve the current infrastructure and match the standard of services provided in developed nations, the government is also encouraging private sector involvement.

Depression among UAE residents is a significant healthcare concern because it results in functional impairment, higher medical expenses, and a burdensome array of symptoms. Major depressive disorder, traffic accidents, and ischemic heart disease were found to be the top three causes of disability-adjusted life years in the UAE, according to the Global Burden of Disease survey from 2010. One in every four residents of the UAE suffers from mental health issues, making it the country with the greatest regional prevalence of depression. 5.1% of the population meets the diagnostic requirements for depression and anxiety, two of the most prevalent diagnoses.

The new nasal spray is now being used by the biggest healthcare system in the UAE to treat and manage people with severe depression. According to the physicians of Abu Dhabi Health Services Company, Esketamine nasal spray offers relief to people who have attempted other antidepressant treatments but with little to no success. After receiving approval from both the European Medicines Agency and the US Food and Drug Administration (FDA), the medication was recognized in the UAE in 2020.

UAE Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

The UAE has recently experienced a rise in mental health awareness, which has stimulated a greater acceptance and openness toward depression. This has made it more likely that people will seek treatment by lowering the stigma involved in the condition. The advancement of the novel, more potent treatments for depression is gaining more and more popularity. As a result, there has been an increase in investment in R&D efforts in the UAE, which is predicted to spur market development. To advance mental health services in the nation, the UAE government has started several schemes. To enhance mental health services and reduce the stigma surrounding mental health disorders, the National Mental Health Program, example, was introduced in 2019. The UAE depression therapeutics market is projected to develop as a result of these programs.

Market Restraints

Even though the UAE is becoming more aware of mental health problems, there is still a lack of knowledge about depression and its treatment. Delays in getting treatment may result from this, which may restrict the market's expansion. The UAE has the lowest attendance rate for youth at mental health centres. Families and young people in need of immediate help with their mental or behavioural health, as well as those in need of addiction treatment, are more likely to travel overseas for psychiatric care. Mental health disorders still carry a cultural stigma in some regions of the UAE, which may deter some people from getting help. This may reduce the need for depression treatments and halt the UAE depression therapeutics market's expansion.

Competitive Landscape

Key Players

Al Hayat Pharmaceuticals (ARE)
Pharmatrade (ARE)
Al Waha Pharmaceutical (ARE)
Sahara Pharmaceutical (ARE)
Viatris (ARE)
Allergan
Takeda Pharmaceutical
Intellipharmaceutics
Otsuka Holdings
H.Lundbeck
Apotex

Healthcare Policies and Regulatory Landscape

Depending on the sort of treatment and the healthcare provider, different depression therapeutics are reimbursed under different policies in the UAE. In most cases, patients are required to pay for their care upfront before submitting a claim to their insurance company for repayment. For patients, the procedure can be made simpler by some providers who give direct billing to insurance companies. The majority of insurance providers in the UAE support mental health conditions, including depression. On the other hand, coverage may differ based on the sort of policy and the insurer. A wider range of services may be covered by some policies, while others may have restrictions on the number of therapy sessions or prescription drugs that can be covered. The National Mental Health Program is one of the initiatives the UAE government has initiated to enhance mental health care in the nation. The government has pledged to improve access to care, increase funding for mental health services, and mitigate the stigma attached to mental health disorders as part of this initiative. These regulations should enhance insurance coverage and payment practices for depression treatment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

Antidepressants
Anxiolytics
Anticonvulsants
Noradrenergic Agents
Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

Electroconvulsive Therapy (ECT)
Cognitive Behaviour Therapy (CBT)
Psychotherapy
Deep Brain Stimulation
Transcranial Magnetic Stimulation (TMS)
Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

Major Depressive Disorder (MDD)
Bipolar Disorder
Dysthymic Disorder
Postpartum Depression
Seasonal Affective Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Others

By End Users (Revenue, USD Billion):

NGOs
Asylums
Hospitals
Mental Healthcare Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.